Faruqi &amp; Faruqi, LLP 证券诉讼合伙人 James (Josh) Wilson 鼓励在 Inspire Medical 中遭受损失的投资者直接联系他以讨论他们的选择
如果您在 2024 年 8 月 6 日至 2025 年 8 月 4 日期间购买或获得了 Inspire Medical 的证券，并希望讨论您的法律权利，请直接致电 Faruqi &amp; Faruqi 合伙人 Josh Wilson，电话 877-247-4292 或 212-983-9330 (Ext. 1310)。
[您也可以点击这里获取更多信息]
, /PRNewswire/ -- Faruqi &amp; Faruqi, LLP 是一家领先的全国性证券法律事务所，正在调查对 Inspire Medical Systems, Inc.（&#34;Inspire Medical&#34; 或 &#34;公司&#34;）(NYSE: INSP) 的潜在索赔，并提醒投资者注意 2026 年 1 月 5 日的截止日期，以寻求在针对公司的联邦证券集体诉讼中担任主原告的角色。
继续阅读
<img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/>
James (Josh) Wilson，Faruqi &amp; Faruqi 高级合伙人 (PRNewsfoto/Faruqi &amp; Faruqi, LLP)
Faruqi &amp; Faruqi 是一家领先的全国性证券法律事务所，在纽约、宾夕法尼亚、加利福尼亚和乔治亚州设有办事处。自 1995 年成立以来，该事务所已为投资者追回数亿美元。请访问 www.faruqilaw.com。
如下面详细说明，投诉指控公司及其高管违反联邦证券法，发布虚假和/或误导性陈述和/或未披露关于 Inspire V 的关键信息，包括该设备的实际市场需求以及公司是否采取了成功推出所需的步骤。被告发布了一系列实质上虚假和误导性的声明，导致投资者相信 Inspire V 的需求强劲，公司已采取必要步骤以确保成功推出。
2025 年 8 月 4 日，Inspire Medical Systems 宣布其新 Inspire V 设备的推出遭遇重大挫折。公司透露，由于许多治疗中心尚未完成所需的培训、合同签署和入职流程，推出进展远比预期缓慢。Inspire 还披露了账单和报销方面的挑战，解释称尽管 Medicare 已批准了 Inspire V 的 CPT 代码，但用于索赔处理的必要软件更新直到 7 月 1 日才生效。因此，植入中心在此日期之前无法对手术进行收费，而是继续使用较旧的 Inspire IV 系统。
除了这些后勤和报销问题外，Inspire 报告称 Inspire V 的推出面临需求疲软和库存过剩的问题。这些问题迫使公司将其 2025 年的盈利指引大幅下调超过 80%。在这些消息披露后，Inspire 的股价在一天内下跌超过 32%——从 2025 年 8 月 4 日的每股 129.95 美元跌至 2025 年 8 月 5 日的每股 87.91 美元——市值蒸发约 12 亿美元。
法院指定的主原告是对集体所寻求的救济具有最大财务利益的投资者，该投资者是适合且典型的集体成员，代表假定集体指导和监督诉讼。任何假定集体的成员可以通过其选择的律师向法院申请担任主原告，或者选择不采取任何行动，保持缺席集体成员的身份。您参与任何赔偿的能力不受担任主原告与否的决定影响。
Faruqi &amp; Faruqi, LLP 还鼓励任何了解 Inspire Medical 行为的信息人士与该事务所联系，包括举报人、前员工、股东等。
要了解更多关于 Inspire Medical 集体诉讼的信息，请访问 www.faruqilaw.com/INSP 或 直接致电 Faruqi &amp; Faruqi 合伙人 Josh Wilson，电话 877-247-4292 或 212-983-9330 (Ext. 1310)。
请在 LinkedIn、X 或 Facebook 上关注我们以获取更新。
律师广告。负责此广告的法律事务所为 Faruqi &amp; Faruqi, LLP (www.faruqilaw.com)。之前的结果不保证或预测任何未来事项的类似结果。我们欢迎讨论您的具体案件的机会。所有通信将被视为保密。
来源 Faruqi &amp; Faruqi, LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE3Jk5ld3NJdGVtSWQ9Tlk0OTA4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTcxMDA2UFJfTkVXU19VU1BSX19fX19OWTQ5MDg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE3Jk5ld3NJdGVtSWQ9Tlk0OTA4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTcxMDA2UFJfTkVXU19VU1BSX19fX19OWTQ5MDg4"/>

启迪医疗

Faruqi & Faruqi, LLP 正在调查针对启迪医疗（Inspire Medical Systems, Inc.）的潜在索赔，因其 allegedly 对市场需求和 Inspire V 设备的推出做出了虚假陈述。该公司面临了一些挫折，包括培训延迟和账单问题，导致股价大幅下跌。投资者被鼓励在 2026 年 1 月 5 日的联邦证券集体诉讼截止日期之前，联系该公司讨论法律选项

Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspire Medical To Contact Him Directly To Discuss Their Options
<div class="lb-trans">Faruqi &amp; Faruqi, LLP 证券诉讼合伙人 James (Josh) Wilson 鼓励在 Inspire Medical 中遭受损失的投资者直接联系他以讨论他们的选择
</div>If you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
<div class="lb-trans">如果您在 2024 年 8 月 6 日至 2025 年 8 月 4 日期间购买或获得了 Inspire Medical 的证券，并希望讨论您的法律权利，请直接致电 Faruqi &amp; Faruqi 合伙人 Josh Wilson，电话 877-247-4292 或 212-983-9330 (Ext. 1310)。
</div>[You may also click here for additional information]
<div class="lb-trans">[您也可以点击这里获取更多信息]
</div>, /PRNewswire/ -- Faruqi &amp; Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inspire Medical Systems, Inc. (&#34;Inspire Medical&#34; or the &#34;Company&#34;) (NYSE: INSP) and reminds investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
<div class="lb-trans">, /PRNewswire/ -- Faruqi &amp; Faruqi, LLP 是一家领先的全国性证券法律事务所，正在调查对 Inspire Medical Systems, Inc.（&#34;Inspire Medical&#34; 或 &#34;公司&#34;）(NYSE: INSP) 的潜在索赔，并提醒投资者注意 2026 年 1 月 5 日的截止日期，以寻求在针对公司的联邦证券集体诉讼中担任主原告的角色。
</div>Continue Reading
<div class="lb-trans">继续阅读
</div><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/>
James (Josh) Wilson, Faruqi &amp; Faruqi Senior Partner (PRNewsfoto/Faruqi &amp; Faruqi, LLP)
<div class="lb-trans">James (Josh) Wilson，Faruqi &amp; Faruqi 高级合伙人 (PRNewsfoto/Faruqi &amp; Faruqi, LLP)
</div>Faruqi &amp; Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
<div class="lb-trans">Faruqi &amp; Faruqi 是一家领先的全国性证券法律事务所，在纽约、宾夕法尼亚、加利福尼亚和乔治亚州设有办事处。自 1995 年成立以来，该事务所已为投资者追回数亿美元。请访问 www.faruqilaw.com。
</div>As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose key facts about Inspire V, including the actual market demand for the device and whether the company had taken the steps necessary to successfully launch it. Defendants issued a series of materially false and misleading statements that led investors to believe demand for Inspire V was strong and that Company had taken the necessary steps for a successful launch.
<div class="lb-trans">如下面详细说明，投诉指控公司及其高管违反联邦证券法，发布虚假和/或误导性陈述和/或未披露关于 Inspire V 的关键信息，包括该设备的实际市场需求以及公司是否采取了成功推出所需的步骤。被告发布了一系列实质上虚假和误导性的声明，导致投资者相信 Inspire V 的需求强劲，公司已采取必要步骤以确保成功推出。
</div>On August 4, 2025, Inspire Medical Systems announced significant setbacks in the launch of its new Inspire V device. The company revealed that the rollout was taking much longer than expected because many treatment centers had not yet completed the required training, contracting, and onboarding needed to begin using the product. Inspire also disclosed billing and reimbursement challenges, explaining that although Medicare had approved a CPT code for Inspire V, the necessary software updates for claims processing did not go into effect until July 1. As a result, implanting centers could not bill for procedures before that date and instead continued using the older Inspire IV system.
<div class="lb-trans">2025 年 8 月 4 日，Inspire Medical Systems 宣布其新 Inspire V 设备的推出遭遇重大挫折。公司透露，由于许多治疗中心尚未完成所需的培训、合同签署和入职流程，推出进展远比预期缓慢。Inspire 还披露了账单和报销方面的挑战，解释称尽管 Medicare 已批准了 Inspire V 的 CPT 代码，但用于索赔处理的必要软件更新直到 7 月 1 日才生效。因此，植入中心在此日期之前无法对手术进行收费，而是继续使用较旧的 Inspire IV 系统。
</div>In addition to these logistical and reimbursement problems, Inspire reported that the Inspire V launch was suffering from weak demand and excess inventory. These issues forced the company to sharply cut its 2025 earnings guidance by more than 80%. Following these revelations, Inspire's stock price fell more than 32% in a single day—from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025—wiping out approximately $1.2 billion in market capitalization.
<div class="lb-trans">除了这些后勤和报销问题外，Inspire 报告称 Inspire V 的推出面临需求疲软和库存过剩的问题。这些问题迫使公司将其 2025 年的盈利指引大幅下调超过 80%。在这些消息披露后，Inspire 的股价在一天内下跌超过 32%——从 2025 年 8 月 4 日的每股 129.95 美元跌至 2025 年 8 月 5 日的每股 87.91 美元——市值蒸发约 12 亿美元。
</div>The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
<div class="lb-trans">法院指定的主原告是对集体所寻求的救济具有最大财务利益的投资者，该投资者是适合且典型的集体成员，代表假定集体指导和监督诉讼。任何假定集体的成员可以通过其选择的律师向法院申请担任主原告，或者选择不采取任何行动，保持缺席集体成员的身份。您参与任何赔偿的能力不受担任主原告与否的决定影响。
</div>Faruqi &amp; Faruqi, LLP also encourages anyone with information regarding Inspire Medical's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
<div class="lb-trans">Faruqi &amp; Faruqi, LLP 还鼓励任何了解 Inspire Medical 行为的信息人士与该事务所联系，包括举报人、前员工、股东等。
</div>To learn more about the Inspire Medical class action, go to www.faruqilaw.com/INSP or call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
<div class="lb-trans">要了解更多关于 Inspire Medical 集体诉讼的信息，请访问 www.faruqilaw.com/INSP 或 直接致电 Faruqi &amp; Faruqi 合伙人 Josh Wilson，电话 877-247-4292 或 212-983-9330 (Ext. 1310)。
</div>Follow us for updates on LinkedIn, on X, or on Facebook.
<div class="lb-trans">请在 LinkedIn、X 或 Facebook 上关注我们以获取更新。
</div>Attorney Advertising. The law firm responsible for this advertisement is Faruqi &amp; Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
<div class="lb-trans">律师广告。负责此广告的法律事务所为 Faruqi &amp; Faruqi, LLP (www.faruqilaw.com)。之前的结果不保证或预测任何未来事项的类似结果。我们欢迎讨论您的具体案件的机会。所有通信将被视为保密。
</div>SOURCE Faruqi &amp; Faruqi, LLP
<div class="lb-trans">来源 Faruqi &amp; Faruqi, LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjE3Jk5ld3NJdGVtSWQ9Tlk0OTA4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMTcxMDA2UFJfTkVXU19VU1BSX19fX19OWTQ5MDg4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY49088&amp;Transmission_Id=202512171006PR_NEWS_USPR_____NY49088&amp;DateId=20251217"/>

股东警示：Faruqi & Faruqi, LLP 正在代表启迪医疗系统的投资者调查索赔